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Objective. To evaluate the impact of anti–tumor necrosis factor (anti-TNF) therapies on quality of life (QOL) and
functional status in psoriatic arthritis (PsA) patients and study potential predictors for QOL improvements.
Methods. The study was based on a cohort of 596 PsA patients receiving anti-TNF therapies. Changes in functional status
and QOL were assessed using the Health Assessment Questionnaire (HAQ) and Short Form 36 (SF-36) questionnaire on
a 6-month basis. The Short Form 6D (SF-6D) was calculated as a utility score. Univariate and multivariate linear
regression models were developed to examine potential predictors of QOL improvements at 6 months, using a range of
demographic, baseline disease-speciﬁc, and therapeutic variables.
Results. At 6 months, signiﬁcant improvements in all SF-36 subscale scores were found, with the greatest percentage
improvement from baseline related to physical role (113.8%; 95% conﬁdence interval [95% CI] 102.6, 125.0). The percent
improvement for the physical component scale was 53.2% (95% CI 44.5, 61.9) at 6 months, whereas that for the mental
component scale was 16.9% (95% CI 14.7, 19.2). The mean  SD SF-6D score was 0.58  0.07 at baseline, and this
improved to 0.63  0.06 at 6 months. The median HAQ score at baseline was 1.88 (interquartile range [IQR] 1.38–2.25)
for the entire cohort, and this improved to 1.25 (IQR 0.63–1.88) at 6 months. Improvements in Disease Activity Score in
28 joints at 6 months were found to be signiﬁcantly associated with QOL improvements at the same time point.
Conclusion. Anti-TNF therapy is associated with improvement in both physical and mental status in PsA patients. These
improvements were most substantial in patients who also had improvements in their disease activity.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂammatory condi-
tion occurring in 0.2–1% of the general population (1,2)
and 6–39% of patients with psoriasis (3–5). Both the joint
and skin components of the disease have a profound im-
pact on the quality of life (QOL) of patients with PsA (2,6),
resulting in considerable physical and psychosocial mor-
bidity (7,8). Daily symptoms of fatigue, pain, stiffness, and
physical disability are common features in PsA for many
patients (9). Persistent active disease without effective
treatment may lead to permanent loss of physical function,
reduced productivity, and increased rates of work disabil-
ity (10). Skin involvement is also associated with a signif-
icant emotional burden that negatively impacts patients’
QOL (11).
The impact of anti–tumor necrosis factor (anti-TNF)
therapies (etanercept, inﬂiximab, and adalimumab) on
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345QOL has been studied in PsA in a number of randomized
controlled trials (RCTs) (12–17) and recent longitudinal
observational studies (18,19). However, the RCTs have
only compared individual anti-TNF therapies against pla-
cebo, whereas the observational studies have either in-
cluded no comparator (19) or compared treatment re-
sponse against methotrexate (MTX) (18). To date, to our
knowledge there is no study assessing which factors are
important for predicting QOL improvements in PsA pa-
tients in routine clinical practice. This longitudinal obser-
vational study, therefore, aimed to monitor the impact of
anti-TNF therapies on QOL and functional status of PsA
patients, and to identify which factors (demographic or
clinical) were associated with QOL improvements.
PATIENTS AND METHODS
Setting. The British Society for Rheumatology Biologics
Register (BSRBR) was established in October 2001. This
multicenter, longitudinal, observational study aims to
monitor the safety and efﬁcacy of biologic therapies in
patients with inﬂammatory arthropathies in the UK (20).
Although it is primarily a study of patients with rheuma-
toid arthritis (RA), the study also collected data on patients
starting anti-TNF therapies for PsA between 2002 and
2006.
Subjects and treatments. Subjects included in this
study were those included in the BSRBR with a physician
diagnosis of PsA starting 1 of 3 available anti-TNF agents
(etanercept, inﬂiximab, and adalimumab). The British So-
ciety for Rheumatology (BSR) guidelines for the use of
anti-TNF therapies in PsA, published in February 2005,
recommend that anti-TNF drugs should be reserved for
patients with active PsA (deﬁned as 3 tender joints and
3 swollen joints), despite adequate therapeutic trials of at
least 2 standard disease-modifying antirheumatic drugs
(DMARDs) individually or in combination (21). During the
study, etanercept was administered as a subcutaneous in-
jection of 25 mg twice weekly or 50 mg once weekly (22);
adalimumab was administered as a subcutaneous injection
of 40 mg every 2 weeks (23). The licensed dose of inﬂix-
imab is 5 mg/kg administered at weeks 0, 2, 6, and 8, and
then every 8 weeks thereafter. It is also recommended that
inﬂiximab be administered in combination with MTX (24).
Data collection. At the time of initiation of the biologic
drug, details of the patient’s age, sex, diagnosis, disease
duration, and current disease activity (using the 28-joint
count Disease Activity Score [DAS28]) (25) were recorded
by the consultant or rheumatology nurse. Details of past
and present antirheumatic therapies and current comor-
bidities were also recorded. Each patient also provided
details about current work status and ethnicity, and com-
pleted the Health Assessment Questionnaire (HAQ)
adapted for British use (26) and the Short Form 36 (SF-36)
health survey (27).
Rheumatologists and patients were each sent a 6-month
postal followup questionnaire. Rheumatologists recorded
current disease activity (DAS28), while patients com-
pleted the HAQ and SF-36. When questionnaires were not
returned, reminders were sent to the rheumatologists after
5 weeks and to the patients after 2 weeks. Following a
second period of 2 weeks of patient nonresponse, they
were then sent another patient followup questionnaire.
The study was approved by the North West National
Health Service Multicentre Research Ethics Committee
and all of the subjects gave their written consent for
participation.
Statistical analysis. The primary outcome measure was
the change in SF-36 scores (physical component scale
[PCS] and mental component scale [MSC]) at 6 months.
Secondary outcomes included the change in SF-36 scores
between baseline to 12 months and 18 months, as well as
the change in the 8 individual component scales at each
time point.
The Short Form 6D (SF-6D) is a utility score derived
from SF-36 ratings that was computed according to a pub-
lished algorithm (28). It is formed from 11 items included
in the SF-36, which are constructed to form 6 dimensions:
physical functioning, role limitations, social functioning,
pain, mental health, and vitality (28). Each of these 6 di-
mensions has between 4 and 6 possible levels. An SF-6D
health state is deﬁned by selecting one level from each
dimension, through which 18,000 different health states
can be deﬁned. Level 1 in each dimension represents no
loss of health or functioning in that dimension; thus, a
state of “111111” indicates perfect health. In contrast, the
worst possible state is “645 655.” The patient’s current
health state is then valued against the best and the worst
possible health states on a 0–1 scale (based on a UK
population), where 0 is the equivalent to being dead and 1
is the equivalent to perfect health.
Physical function was assessed using the change in the
HAQ score at 6, 12, and 18 months. Paired t-tests (for
the SF-36 and SF-6D) and Wilcoxon’s signed rank test
(for the HAQ) were performed to examine differences
in response between baseline and followup results (at 6,
12, and 18 months) for the cohort as a whole and within
each anti-TNF treatment cohort. Analysis of covariance
(ANCOVA) was used to identify differences between the 3
anti-TNF therapy cohorts adjusting for age, sex, and base-
line values of the HAQ and SF-36 scores. SF-36 PCS, SF-36
MCS, SF-6D, and HAQ scores were computed using 2
approaches: 1) using all available data at each followup,
and 2) imputation of any missing data at each followup,
assuming that data were missing at random, and predicted
using previous scores, patient demographic details, and
disease-speciﬁc and therapeutic variables (29,30).
Univariate and multivariate linear regression models
were used to identify factors associated with changes in
SF-36 scores at 6 months from baseline (31). Separate
models were developed for change in the SF-36 PCS and
SF-36 MCS. The following covariates were examined in
the models: baseline demographic variables (age [years],
sex, whether the patient had additional baseline comor-
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variables (high inﬂammatory markers [C-reactive protein
level 20 mg/liter and/or erythrocyte sedimentation rate
28 mm/hour], 28 tender joint count, and 28 swollen joint
count), HAQ score, disease duration (years), treatment re-
sponse (improvements in the DAS28 at 6 months), and
therapeutic variables (anti-TNF therapy used and concur-
rent use of DMARDs or steroids [yes/no]). In the multi-
variate analyses, we used the 6-month improvement in
the composite DAS28 score as a potential predictor rather
than its individual components at baseline. The results
are presented as  coefﬁcients with corresponding 95%
conﬁdence intervals (95% CIs). All calculations were
performed using Stata, version 9.0 (StataCorp, College
Station, TX).
RESULTS
Demographic characteristics. A total of 596 patients
with PsA were registered with the BSRBR between 2002
and 2006 (333 etanercept, 171 inﬂiximab, and 92 adali-
mumab). Baseline characteristics of the PsA patients are
shown in Table 1. The mean  SD age was 45.7  11.1
years, 53% were women, and the mean  SD disease
duration was 12.4  8.7 years. The median HAQ score was
1.9 (interquartile range [IQR] 1.4–2.3), and the mean  SD
values for the PCS and MCS of the SF-36 were 19.1  9.9
and 41.7  11.6, respectively. There was no signiﬁcant
statistical difference between the 3 anti-TNF cohorts’ de-
mographic characteristics, functional status scores, or
QOL ratings at baseline (Table 1).
QOL. Mean  SD values for the PCS and MCS of the
SF-36 are shown in Table 2. The largest changes were
achieved within the ﬁrst 6 months of treatment and were
largely sustained throughout the followup period to 18
months. For the entire cohort, the mean  SD PCS score
improved from 19.1  9.9 at baseline to 29.3  13.7 at 6
months, whereas the mean  SD MCS score improved from
41.7  11.6 to 48.8  11.7 at the same time points. The
mean  SD SF-6D score was 0.58  0.07 at baseline and
0.63  0.06 at 6 months. Imputing missing variables did not
affect the magnitude of the QOL improvements (Table 2).
The changes from baseline to 6 months were similar for
all 3 anti-TNF agents. For the SF-36 PCS, the mean  SD
improvements were from 18.9  9.9 to 29.4  13.7, from
18.1  9.6 to 27.7  14.1, and from 21.2  10.3 to 31.6 
12.8 for etanercept, inﬂiximab, and adalimumab, respec-
tively. Likewise, mean  SD improvements from baseline
to 6 months for the SF-36 MCS were 41.8  11.5 to 48.7 
12.2 for etanercept, 40.3  10.9 to 48.6  10.9 for inﬂix-
imab, and 44.4  12.5 to 49.2  11.4 for adalimumab. The
mean  SD SF-6D scores were 0.58  0.06, 0.57  0.07,
and 0.59  0.06 at baseline, respectively, and they were
0.63  0.06, 0.62  0.07, and 0.64  0.06 at 6 months for
the abovementioned 3 anti-TNF cohorts, respectively.
There were no signiﬁcant statistical differences in the per-
cent improvement achieved among the 3 cohorts through-
out the followup after adjusting for age, sex, and baseline
values. These improvements were maintained throughout
the followup to 18 months for the 3 cohorts.
At 6 months, the greatest improvements within the
SF-36 instrument from baseline for the entire cohort were
Table 1. Demographic, functional status, and quality of life characteristics of patients with psoriatic arthritis at baseline*
All
(n  596)
Etanercept
(n  333)
Inﬂiximab
(n  171)
Adalimumab
(n  92) P†
Demographic characteristics
Age, years 45.7  11.1 45.8  11.1 44.8  11.0 47.0  11.6 0.325
Women, no. (%) 313 (52.5) 170 (51.1) 94 (55.0) 49 (53.3) 0.581
Disease duration, years 12.4  8.7 12.8  9.0 12.2  8.0 11.4  8.4 0.384
Working status, no. (%)‡ 0.927
Working 245 (41.1) 135 (40.5) 67 (39.2) 43 (46.7)
Unemployed but seeking work 3 (0.5) 2 (0.6) 1 (0.6) 0 (0.0)
Not working due to ill health/disability 146 (24.5) 87 (26.1) 44 (25.7) 15 (16.3)
Retired 70 (11.7) 38 (11.4) 16 (9.4) 16 (17.4)
Functional status and quality of life characteristics
Inﬂammation, no. (%)§ 266 (44.6) 141 (42.3) 85 (49.7) 40 (43.5) 0.143
DAS28 6.4  5.6 6.1  1.2 7.3  10.1 6.0  1.0 0.464
Patient global assessment (100-mm VAS) 71.4  21.1 71.5  20.8 71.1  23.0 71.5  19.0 0.917
HAQ score, median (IQR) 1.9 (1.4–2.3) 1.8 (1.4–2.3) 2.0 (1.4–2.4) 1.8 (1.1–2.3) 0.581
SF-36 PCS 19.14  9.94 18.99  9.93 18.11  9.59 21.19  10.32 0.099
SF-36 MCS 41.73  11.58 41.76  11.55 40.33  10.95 44.43  12.53 0.052
SF-6D 0.58  0.07 0.58  0.06 0.57  0.07 0.59  0.06 0.052
* Values are the mean  SD unless otherwise indicated. DAS28  Disease Activity Score in 28 joints; VAS  visual analog scale; HAQ  Health
Assessment Questionnaire; IQR  interquartile range; SF-36  Short Form 36 questionnaire; PCS  physical component scale; MCS  mental
component scale; SF-6D  Short Form 6D.
† P values are for statistical differences between the 3 anti–tumor necrosis factor cohorts at baseline.
‡ Working status was only available for 77.8% of the patients.
§ C-reactive protein level 20 mg/liter or erythrocyte sedimentation rate 28 mm/hour.
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mean  SD 24.3  26.3 to 52.0  31.1), followed by the
pain component (mean  SD 26.1  19.8 at baseline and
53.6  26.8 at 6 months), whereas the smallest improve-
ments were found in the mental health component (im-
proved from mean  SD 53.7  20.7 to 66.7  21.1), as
shown in Figure 1. The mean  SD values of the 8 domains
of the SF-36 for the PsA cohort over the 18-month fol-
lowup period are detailed in Table 3. ANCOVA tests
showed no signiﬁcant statistical differences in the percent
improvement achieved among the 3 cohorts throughout
the followup period after adjusting for age, sex, and base-
line values (data not shown).
Functional status. The median HAQ score at baseline
was 1.88 (IQR 1.38–2.25) for the entire cohort, and this
improved to 1.25 (IQR 0.63–1.88) at 6 months (P  0.001)
(Table 2). Imputing missing variables did not affect the
magnitude of the improvements observed for physical
function. The median HAQ score improved from 1.75
(IQR 1.38–2.25) at baseline to 1.38 (IQR 0.50–1.88) at
6 months in the etanercept cohort, from 2.00 (IQR 1.38–
2.38) at baseline to 1.25 (0.63–2.00) at 6 months in the
inﬂiximab cohort, and from 1.75 (IQR 1.13–2.25) at base-
line to 1.19 (0.63–1.88) at 6 months in the adalimumab
cohort. These responses were generally maintained for
18 months. There were no signiﬁcant statistical differences
in the improvements in HAQ score achieved among the 3
anti-TNF cohorts throughout the followup after adjusting
for age, sex, and baseline values.
Factors associated with QOL improvements at 6
months. Table 4 shows the results from the univariate and
multivariate analyses examining predictors of changes
from baseline in the SF-36 PCS and SF-36 MCS. For the
change in the SF-36 PCS, the univariate analyses suggested
that for each year increase in the patient’s age, there was a
lower improvement in the SF-36 PCS values (  0.14;
95% CI 0.25, 0.04). Patients who were not working due
to ill health or disability (  5.34; 95% CI 8.05, 2.63)
and those who were retired (  5.11; 95% CI 9.34,
Figure 1. Spider plot of the mean scores at baseline and 6 months
in the Short Form 36 components for patients with psoriatic
arthritis receiving anti–tumor necrosis factor therapies.
Table 2. Scores of quality of life and functional status in patients with
psoriatic arthritis*
Available data at
each followup
Imputation of missing
values†
SF-36 PCS
Baseline (n  510) 19.14  9.94 19.14  9.94
6 months (n  400) 29.32  13.69 28.27  12.19
12 months (n  363) 29.12  13.24 28.52  12.32
18 months (n  317) 29.34  13.91 27.59  12.68
SF-36 MCS
Baseline (n  510) 41.73  11.58 41.73  11.58
6 months (n  400) 48.79  11.67 47.86  11.12
12 months (n  363) 47.74  11.64 47.20  11.23
18 months (n  317) 48.58  11.95 47.52  11.57
SF-6D
Baseline (n  510) 0.58  0.07 0.58  0.07
6 months (n  400) 0.63  0.06 0.62  0.05
12 months (n  363) 0.63  0.06 0.62  0.06
18 months (n  317) 0.63  0.07 0.63  0.06
HAQ score, median (IQR)
Baseline (n  562) 1.88 (1.38–2.25) 1.88 (1.38–2.25)
6 months (n  424) 1.25 (0.63–1.88) 1.27 (0.65–1.89)
12 months (n  382) 1.38 (0.63–2.00) 1.39 (0.64–2.01)
18 months (n  344) 1.38 (0.63–2.00) 1.39 (0.64–2.01)
* Values are the mean  SD unless otherwise indicated. SF-36  Short Form 36; PCS  physical
component scale; MCS  mental component scale; SF-6D  Short Form 6D; HAQ  Health Assessment
Questionnaire; IQR  interquartile range.
†N 510 for quality of life scores and n  562 for physical function score.
348 Saad et al0.88) had signiﬁcantly lower SF-36 PCS values at 6
months compared with patients who were working. How-
ever, the presence of inﬂammation was associated with a
greater improvement in the SF-36 PCS (  3.15; 95% CI
0.75, 5.55), as did a higher baseline swollen joint count
(  0.30 per additional swollen joint; 95% CI 0.09, 0.51).
In addition to baseline factors, improvements in DAS28
scores at 6 months were also strongly associated with
improvements in SF36 PCS scores from baseline (  3.09
per unit improvement in DAS28; 95% CI 2.37, 3.81).
In the multivariate analysis, there was a statistically
signiﬁcant association between the improvement in SF-36
Table 3. Values of the 8 domains of the Short Form 36 in patients with psoriatic arthritis at different followup times*
Baseline 6 months 12 months 18 months
Physical function 27.43  23.61 (537) 43.91  29.16 (407) 42.56  29.33 (377) 44.36  29.59 (343)
Role (physical) 24.33  26.34 (541) 52.01  31.05 (430) 51.30  31.52 (379) 53.65  31.23 (344)
Bodily pain 26.09  19.83 (550) 53.62  26.79 (436) 53.23  26.99 (390) 52.58  27.14 (351)
General health 28.44  18.26 (543) 39.96  22.43 (420) 39.89  21.89 (378) 40.99  22.21 (344)
Vitality 25.75  20.06 (541) 40.79  22.82 (430) 40.47  23.09 (383) 40.72  23.42 (352)
Social function 36.43  25.22 (546) 62.16  28.75 (427) 60.58  29.05 (390) 62.15  28.89 (350)
Role (emotional) 47.47  35.97 (546) 69.07  30.51 (429) 67.12  31.02 (385) 69.35  30.97 (346)
Mental health 53.68  20.72 (540) 66.66  21.11 (428) 65.11  22.13 (383) 67.27  22.18 (353)
* Values are the mean  SD (no.). P  0.05 was calculated for each followup versus baseline within the same cohort.
Table 4. Univariate and multivariate regression analysis of potential predictors and factors associated with changes in the
PCS and MCS of the SF-36 at 6 months*
Change in SF-36 PCS Change in SF-36 MCS
Univariate Multivariate Univariate Multivariate
Demographic variables
Age at start of therapy, years 0.14 (0.25, 0.04)† 0.02 (0.17, 0.14) 0.08 (0.03, 0.19) 0.09 (0.10, 0.28)
Women 1.73 (4.06, 0.60) 0.67 (2.10, 3.44) 0.01 (2.46, 2.47) 0.95 (2.34, 4.24)
Baseline comorbidity (yes/no)‡ 0.40 (2.11, 2.92) 0.19 (2.68, 3.05) 0.96 (3.63, 1.72) 1.99 (5.39, 1.41)
Working status (working is the
reference group)
Unemployed but seeking work 10.37 (4.82, 25.57) 7.94 (6.93, 22.83) 13.26 (2.97, 29.49) 7.15 (10.52, 24.83)
Not working due to ill health/
disability
5.34 (8.05, 2.63)† 4.64 (7.71, 1.58)† 1.33 (1.56, 4.22) 2.44 (1.20, 6.08)
Retired 5.11 (9.34, 0.88)† 4.49 (9.52, 0.55) 1.14 (5.66, 3.38) 0.39 (5.59, 6.38)
Disease variables
Baseline HAQ score 0.13 (1.38, 1.12) 0.22 (1.51, 1.08) 0.99 (0.34, 2.31) 0.34 (1.88, 1.20)
Disease duration, years 0.07 (0.08, 0.21) 0.09 (0.26, 0.08) 0.18 (0.03, 0.34)† 0.10 (0.10, 0.30)
Baseline inﬂammation§ 3.15 (0.75, 5.55)† – 2.07 (0.49, 4.62) –
Baseline tender joint count 0.10 (0.06, 0.26) – 0.01 (0.16, 0.17) –
Baseline swollen joint count 0.30 (0.09, 0.51)† – 0.21 (0.02, 0.43) –
Treatment response
Improvement in DAS28 at 6
months
3.09 (2.37, 3.81)† 2.92 (2.10, 3.75)† 3.09 (2.37, 3.81)† 1.31 (0.33, 2.29)†
Therapeutic variable: concurrent use
DMARDs 1.61 (0.76, 3.98) 2.07 (0.79, 4.93) 1.03 (1.49, 3.56) 0.56 (3.96, 2.84)
Steroids 1.43 (1.57, 4.42) 1.60 (1.46, 4.66) 3.77 (0.52, 7.02)† 2.38 (1.25, 6.02)
Biologic therapy (etanercept is the
reference category)
Inﬂiximab 2.21 (4.94, 0.54) 0.93 (2.50, 4.35) 1.02 (3.94, 1.90) 2.54 (1.53, 6.61)
Adalimumab 0.25 (3.04, 3.54) 0.08 (4.19, 4.36) 1.97 (5.49, 1.54) 3.88 (1.19, 8.95)
* Values are the  coefﬁcient (95% conﬁdence interval). PCS  physical component scale; MCS  mental component scale; SF-36  Short Form 36;
HAQ  Health Assessment Questionnaire; DAS28  Disease Activity Score in 28 joints; DMARDs  disease-modifying antirheumatic drugs.
† P  0.05.
‡ Includes any of hypertension, angina, ischemic heart disease, stroke, pulmonary ﬁbrosis, asthma, chronic obstructive pulmonary disease, diabetes
mellitus, thyroid disease, peptic ulcers, hepatic disease, renal disease, demyelinating disease, epilepsy, depression, tuberculosis, or cancer.
§ C-reactive protein level 20 mg/liter or erythrocyte sedimentation rate 28 mm/hour.
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per unit improvement in DAS28; 95% CI 2.10, 3.75). Those
patients who were not working due to ill health or disabil-
ity rather than working at the start of therapy had signiﬁ-
cantly lower SF-36 PCS scores at 6 months (  4.64;
95% CI 7.71, 1.58) (Table 4).
For the change in SF-36 MCS at 6 months, both the
univariate and multivariate models found that patients
showing improvements in their DAS28 score at 6 months
(  3.09 per unit improvement in DAS28; 95% CI 2.37,
3.81 and   1.31 per unit improvement in DAS28; 95% CI
0.33, 2.29, respectively) experienced improvements in
their SF-36 MCS. In the univariate analysis, patients with
a longer disease duration (  0.18 per year; 95% CI 0.03,
0.34) or receiving concurrent steroids (3.77; 95% CI 0.52,
7.02) showed greater improvements at 6 months, but these
ﬁndings did not persist when controlling for other poten-
tial confounding variables in the multivariate analysis.
DISCUSSION
This study has shown that, in addition to controlling dis-
ease activity, the anti-TNF agents can signiﬁcantly im-
prove physical disability and QOL during routine clinical
use. The greatest improvements were seen in the SF-36
PCS and the HAQ, with smaller improvements observed in
the SF-36 MCS. These improvements were attained at 6
months and were maintained thereafter. Imputation of
missing variables at followup did not affect the magnitude
of the improvements observed. There was no statistically
signiﬁcant difference in the reported improvements among
the 3 anti-TNF agents, although modest differences in
treatment persistence among them have previously been
reported (32).
Unlike for RA, in PsA there are no speciﬁc correlates
of changes in either HAQ or SF-36 scores with a minimum
clinically important difference (MCID). However, using
data from RA, the mean clinical difference in HAQ score
at 6 months of 0.63 was far greater than the change of
0.22 HAQ units speciﬁed as the MCID for RA (33). Like-
wise, the mean clinical differences at 6 months of 10.2 in
the SF-36 PCS and 7.06 in the SF-36 MCS were greater
than the MCIDs speciﬁed for RA (4.4 units on the SF-36
PCS and 3.1 units on the SF-36 MCS) (34).
The study has also shown that improvements in the
QOL of patients treated with anti-TNF therapies reported
in PsA are much higher than those reported in RA and
slightly higher than those reported in ankylosing spondy-
litis (AS) (35). Similarly, a study from the Norwegian
DMARD register (36) found larger improvements, after 1
year of anti-TNF therapy, in the QOL of patients with PsA
(n  172) and AS (n  249) compared with patients with
RA (n  847), which contributed to the better retention of
patients with their treatments in the PsA (77.3%) and AS
(77.5%) cohorts of the register compared with the RA
cohort (65.4%). Our results also correspond with those
observed during RCTs involving 1,990 inﬂiximab-treated
patients with PsA, AS, and RA, where the greatest im-
provements from baseline were observed in the physical
role and bodily pain components of the SF-36 (19). Fur-
thermore, the same 2 domains of the SF-36 showed the
greatest improvements from baseline in PsA patients
treated with adalimumab (n  151) (37). Patients with PsA
treated with etanercept (n  71) have also reported a
signiﬁcant reduction in disability and an increase in func-
tional capacity (38).
It has also been found that improvements in QOL in PsA
patients (n  146) treated with anti-TNF therapies were
superior to PsA patients treated with MTX (n  380) (18).
QOL changes from baseline to 6 months were statistically
signiﬁcant in favor of anti-TNF therapy for only 4 (bodily
pain, vitality, physical role, and general health) of the 8
domains of the SF-36.
To our knowledge, this is the ﬁrst study that has re-
ported on those factors that could either predict (measured
at baseline) or were associated with (measured at 6
months) improvements in QOL for patients with PsA. The
ﬁndings suggest that not working due to ill health or dis-
ability was associated with negative impacts on the PCS of
the SF-36, which may be a further marker for disease
severity independent of disease activity. Not surprisingly,
improvements in QOL were also signiﬁcantly associated
with improvements in disease activity. Although the sim-
pliﬁed disease activity score (DAS28) was originally de-
veloped for RA, it has also been shown to perform better
than the Psoriatic Arthritis Response Criteria (PsARC) in
RCTs of PsA (39), and to be discriminant and responsive in
observational cohorts of PsA (40).
Because the BSRBR was originally developed as an RA
register, a limitation to the analysis is that there are certain
aspects of the patient’s PsA that were not captured, such as
the Psoriasis Area and Severity Index scores and whether
or not there was also axial involvement that may also have
inﬂuenced improvements in QOL. Second, as data were
collected on a 6-month basis, the analysis precludes a
more detailed analysis of the time to initial improvement
in utility development (41). A Swedish study of anti-TNF
use in RA, PsA, and other spondylarthropathies has sug-
gested that utility improvements occur rapidly (within 2
weeks) and were maintained thereafter (41).
Our results reﬂect current experience in the use of anti-
TNF therapies in patients with PsA in the UK. These
ﬁndings should be considered in context with the guide-
lines published by the BSR (21) and the National Institute
for Health and Clinical Excellence for PsA (42,43). The
guidelines suggest a minimum level of disease activity (at
least 3 swollen joints and 3 tender joints despite 2 stan-
dard DMARDs) and treatment thresholds included the
PsARC. However, neither of the guidelines includes
thresholds for improvements in QOL. Although there have
been previous efforts to develop speciﬁc tools to measure
QOL in PsA (44,45), these tools have not been introduced
to routine practice (46).
The ﬁndings in this observational study provide a more
solid basis for health economic modeling compared with
RCT data due to the greater external validity of the former
(47). As policymakers need cost-effectiveness information
that is both internally and externally valid, their decisions
should be based on data evolving from routine clinical
350 Saad et alpractice. Furthermore, the use of a generic utility instru-
ment (SF-6D) makes comparisons across different diag-
noses and future quality-adjusted life year calculations
possible. Although criticisms regarding the SF-6D exist
that suggest that it may be less acceptable to the patient
compared with the EuroQol, with the risk of more incom-
plete answers, the EuroQol may underestimate utility in
less severe disease states (48).
The HAQ was originally developed for RA (49), but has
recently been validated for PsA (50). It has been exten-
sively used for measuring physical function in clinical
trials and observational studies (51,52), and has been
shown to be adequately sensitive to peripheral disease
improvements after anti-TNF therapies in PsA (13,17). It is
interesting to note that improvements in functional status
as measured by the HAQ paralleled the improvements in
the QOL as measured by the SF-36 questionnaire, indicat-
ing the close relationship between both domains. In RA, it
has been shown that, particularly in later disease, the HAQ
score is a composite of both a reversible (inﬂammation)
and irreversible (damage) component (53). The signiﬁcant
improvement in HAQ score in the patients in this study,
despite a mean disease duration of 12 years, suggests a
signiﬁcant reversible component within the HAQ score in
PsA as well.
Further work is required to determine the MCID thresh-
olds in the HAQ and SF-36 that are speciﬁc for PsA,
because given the impact of skin disease and other extra-
articular manifestations, it cannot be assumed that values
for RA will be the same for PsA. Equally important is the
need to investigate whether subsequent switching of anti-
TNF therapies will predict QOL changes. A recent study of
the RA cohort within the BSRBR found that the functional
status of those who switched treatment improved with a
second anti-TNF agent despite failure of the ﬁrst drug (54).
Data from Sweden have demonstrated that QOL improve-
ments during the ﬁrst and second anti-TNF courses were
similar in PsA (41).
In conclusion, improvements in all domains of QOL and
functional status seen in RCTs with anti-TNF therapies in
PsA can also be seen in routine clinical practice, with
improvements in the PCS being greater than that of the
MCS. There were no statistical differences between the 3
anti-TNF therapies.
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